Nonstructural Protein 4B (NS4B) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Nonstructural Protein 4B (NS4B) – Pipeline Review, H2 2016’, provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics.

The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Nonstructural Protein 4B (NS4B)

The report reviews Nonstructural Protein 4B (NS4B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics and enlists all their major and minor projects

The report assesses Nonstructural Protein 4B (NS4B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Nonstructural Protein 4B (NS4B) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Nonstructural Protein 4B (NS4B)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nonstructural Protein 4B (NS4B) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Gilead Sciences Inc

GlaxoSmithKline Plc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Merck & Co Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Nonstructural Protein 4B (NS4B) Overview 6

Therapeutics Development 7

Nonstructural Protein 4B (NS4B) - Products under Development by Stage of Development 7

Nonstructural Protein 4B (NS4B) - Products under Development by Therapy Area 8

Nonstructural Protein 4B (NS4B) - Products under Development by Indication 9

Nonstructural Protein 4B (NS4B) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Nonstructural Protein 4B (NS4B) - Products under Development by Companies 12

Nonstructural Protein 4B (NS4B) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Nonstructural Protein 4B (NS4B) - Companies Involved in Therapeutics Development 20

Gilead Sciences Inc 20

GlaxoSmithKline Plc 21

Inovio Pharmaceuticals Inc 22

Johnson & Johnson 23

Merck & Co Inc 24

Nonstructural Protein 4B (NS4B) - Drug Profiles 25

GSK-8853 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

INO-8000 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

PTC-512 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

PTC-725 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

PTC-971 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

RL-15A - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Small Molecule to Inhibit NS4B Protein for HCV - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Nonstructural Protein 4B (NS4B) - Dormant Projects 34

Nonstructural Protein 4B (NS4B) - Discontinued Products 35

Nonstructural Protein 4B (NS4B) - Featured News & Press Releases 36

Apr 27, 2016: Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial 36

Oct 21, 2013: Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial 36

Jan 09, 2013: Inovio Pharma To Initiate Clinical Trial For Hepatitis C Therapeutic Vaccine 37

Oct 26, 2009: Wellcome Trust funds dengue fever research in Leuven 38

Aug 10, 2009: PTC Therapeutics Announced Achievement Of Major Milestone In Schering-Plough Hepatitis C Collaboration 39

Mar 20, 2006: Schering-Plough And PTC Therapeutics Announced Collaboration For Development Of PTC's Preclinical Hepatitis C Compounds 39

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by Gilead Sciences Inc, H2 2016 20

Pipeline by GlaxoSmithKline Plc, H2 2016 21

Pipeline by Inovio Pharmaceuticals Inc, H2 2016 22

Pipeline by Johnson & Johnson, H2 2016 23

Pipeline by Merck & Co Inc, H2 2016 24

Dormant Projects, H2 2016 34

Discontinued Products, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared